Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 2,086 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Open Label Extension Study Clear all

Conditions: Schizophrenia, Psychotic Disorders
Interventions: Aripiprazole, Haloperidol, Olanzapine, Oral Paliperidone ER, Perphenazine, Quetiapine, Oral Risperidone, Paliperidone Palmitate Injection (PP1M), Paliperidone Palmitate Injection (PP3M); Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 337 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 34
States / cities: Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 31 more

Conditions: Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
Interventions: SPT-300; Drug
Lead sponsor: Seaport Therapeutics; Industry
Eligibility: 18 Years to 66 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 22
States / cities: Chino, California • Garden Grove, California • Glendale, California + 19 more

Conditions: Parkinson's Disease
Interventions: E2007; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 9
States / cities: Peoria, Arizona • Little Rock, Arkansas • Oxnard, California + 6 more

Conditions: Hepatic Impairment
Interventions: Nalbuphine ER; Drug
Lead sponsor: Trevi Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida

Conditions: Amyotrophic Lateral Sclerosis, ALS
Interventions: Placebo, Ravulizumab; Drug · Biological
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 34
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Loma Linda, California + 27 more

Conditions: Sanfilippo Syndrome, Mucopolysaccharidosis (MPS)
Interventions: HGT-1410; Drug
Lead sponsor: Shire; Industry
Eligibility: 12 Months to 48 Months
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Chapel Hill, North Carolina

Conditions: Vitiligo
Interventions: Ruxolitinib cream, Vehicle cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 26
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Rogers, Arkansas + 21 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Placebo, Test Product (tiotropium bromide inhalation powder), Reference Product (Spiriva®); Drug
Lead sponsor: Lupin, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 34
States / cities: Andalusia, Alabama • Jasper, Alabama • Glendale, Arizona + 28 more

Conditions: Hunter Syndrome
Interventions: Idursulfase-IT, Elaprase; Drug
Lead sponsor: Shire; Industry
Eligibility: Up to 18 Years · Male only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 3
States / cities: Oakland, California • Chicago, Illinois • Chapel Hill, North Carolina

Conditions: Epidermal Nevus Syndrome
Interventions: Crysvita (burosumab-twza) Treatment; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 6 Months and older · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Alzheimer's Disease
Interventions: Placebo, Bepranemab; Other · Biological
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 40
States / cities: Fresno, California • Fullerton, California • Irvine, California + 34 more

Conditions: Diabetes Mellitus
Interventions: Alogliptin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 3,323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 62
States / cities: Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 59 more

Conditions: Intermittent Claudication
Interventions: Cilostazol Tablet 100 mg, PMR Tablet 135 mg; Drug
Lead sponsor: Genovate Biotechnology Co., Ltd.,; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Atopic Dermatitis
Interventions: Tapinarof cream, 1%; Drug
Lead sponsor: Organon and Co; Industry
Eligibility: 2 Years and older
Enrollment: 728 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 102
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 88 more

Conditions: Cystic Fibrosis
Interventions: ELX/TEZ/IVA, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 52
States / cities: Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 47 more

Conditions: Hemophilia A, Hemophilia B
Interventions: Fitusiran (SAR439774); Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Pittsburgh, Pennsylvania

Conditions: Achondroplasia
Interventions: Infigratinib; Drug
Lead sponsor: QED Therapeutics, a BridgeBio company; Industry
Eligibility: 3 Years to 18 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 8
States / cities: Oakland, California • Aurora, Colorado • Wilmington, Delaware + 5 more

Conditions: Migraine
Interventions: Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing, Placebo comparator dosing; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 30
States / cities: Tempe, Arizona • Colton, California • Los Angeles, California + 27 more

Conditions: Systemic Lupus Erythematosus
Interventions: Placebo, Belimumab 200 mg SC, Standard therapy; Biological · Drug
Lead sponsor: Human Genome Sciences Inc., a GSK Company; Industry
Eligibility: 18 Years and older
Enrollment: 839 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 82
States / cities: Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 68 more

Conditions: Schizophrenia
Interventions: Brexpiprazole; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 17
States / cities: Anaheim, California • Cerritos, California • Escondido, California + 12 more

Conditions: Friedreich's Ataxia
Interventions: Idebenone; Drug
Lead sponsor: Santhera Pharmaceuticals; Industry
Eligibility: 8 Years to 18 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Los Angeles, California • Philadelphia, Pennsylvania

Conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions: Ravulizumab; Biological
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 10
States / cities: Aurora, Colorado • Fort Collins, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Epilepsy
Interventions: Lacosamide Tablet, Lacosamide Oral Solution; Drug
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 16
States / cities: Little Rock, Arkansas • Santa Monica, California • Colorado Springs, Colorado + 13 more

Conditions: Sickle Cell Disease
Interventions: Mitapivat Matched Placebo, Mitapivat; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Indianapolis, Indiana • Grand Rapids, Michigan • Flowood, Mississippi + 2 more

Search by objective public record fields.

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

A Study of E2007 In Patients With Parkinson's Disease

Study of Nalbuphine ER in Participants With Hepatic Impairment

An Efficacy and Safety Study of Ravulizumab in ALS Participants

An Extension Study to Determine Safety and Efficacy for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093.

A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094

A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS)

A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus

BE Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers

Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B

Extension Study of Infigratinib in Children With Achondroplasia (ACH)

Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)

Brexpiprazole in Patients With Schizophrenia

Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures

A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)